Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.56 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL395103 | 0.84 | GSK3B (0.48) | RAB9ANPC1MAPTALDH1A1RECQL | |
| SCHEMBL133449 | 0.81 | PTPN1 (0.59) | MAPTALDH1A1HDAC1SRD5A2 | |
| SCHEMBL135383 | 0.79 | GSK3B (0.55) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL28537498 | 0.79 | KMT2A (0.48) | RAB9AMAPTALDH1A1LMNAMAPK1 | |
| SCHEMBL450084 | 0.78 | RAB9A (0.85) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL7079689 | 0.78 | RAB9A (0.66) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL21652280 | 0.76 | EPHX2 (0.61) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL14918493 | 0.76 | TSHR (0.52) | ALDH1A1ALOX15SRD5A2SMN1; SMN2TP53 | |
| SCHEMBL11770219 | 0.76 | CYP19A1 (0.57) | RAB9ANPC1MAPTALDH1A1LMNA | |
| SCHEMBL5874076 | 0.76 | RAB9A (0.63) | RAB9ANPC1MAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| CN-110272400-B | Synthesis method of 2-trifluoromethyl substituted furan compound and derivative thereof | 福州大学 | 2022-08-23 | — | — | CN | disclosed |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| CN-114163384-A | Method for synthesizing polysubstituted 5-acyl nicotinonitrile | 温州医科大学 | 2022-03-11 | — | — | CN | disclosed |
| US-11124489-B2 | EPAC antagonists | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | CAL POLY CORPORATION | 2021-04-08 | — | — | US | disclosed |
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | CAL POLY CORPORATION | 2021-04-08 | — | — | US | disclosed |
| WO-2021067967-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2020-11-12 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20090102356-A1 | NOVEL ORGANIC COMPOUND HAVING ELECTRON-TRANSPORTING AND/OR HOLE-BLOCKING PERFORMANCE AND ITS USE AND OLEDs COMPRISING THE COMPOUND | TECHNICAL INSTITUTE OF PHYSICS AND CHEMISTRY OF CHINESE ACADEMY OF SCIENCES (CN) | 2009-04-23 | — | — | US | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2005070916-A1 | THIOPHENE AND FURAN COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090102356-A1 | NOVEL ORGANIC COMPOUND HAVING ELECTRON-TRANSPORTING AND/OR HOLE-BLOCKING PERFORMANCE AND ITS USE AND OLEDs COMPRISING THE COMPOUND | SLCO4C1, SLCO1B1, SLCO2B1 | RAB9A 1865/4885NPC1 118/4885MAPT 670/4885 |
| US-20200354373-A1 | HSP90 INHIBITORS AND USES THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | RAB9A 1480/4885NPC1 2456/4885MAPT 494/4885 |
| US-20210101901-A1 | PREPARATION OF PYRAZOLO[3,4-B]PYRIDINES AS ANTIMALARIALS | PNPO, NOX3, G6PD | RAB9A 1213/4885NPC1 2176/4885MAPT 2641/4885 |
| US-11578071-B2 | Preparation of pyrazolo[3,4-B]pyridines as antimalarials | PNPO, NOX3, G6PD | RAB9A 1213/4885NPC1 2176/4885MAPT 2641/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | RAB9A 2462/4885NPC1 1271/4885MAPT 20/4885 |
| US-11312722-B2 | Hsp90 inhibitors and uses thereof | HSP90AB1, HSP90B1, HSP90AA1 | RAB9A 1480/4885NPC1 2456/4885MAPT 494/4885 |
| US-11124489-B2 | EPAC antagonists | EPAS1, GPR139, CRACR2A | RAB9A 526/4885NPC1 3257/4885MAPT 4650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.